Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Swiss pharma giant Roche has released encouraging results from the Phase III SUNMO study showing Lunsumio (mosunetuzumab) administered subcutaneously in combination with Polivy (polatuzumab vedotin), ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

The results for Lunsumio, also known as mosunetuzumab, and Polivy, also known as polatuzumab vedotin, came as part of a phase 3 study. Roche said it would now submit results to global health ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Median OS improved from 12.5 months with rituximab (Rituxan), gemcitabine, and oxaliplatin (R-GemOx) to 19.5 months with the addition of polatuzumab vedotin (Pola-R-GemOx; HR 0.60, 95% CI 0.43-0.83, ...

Polivy is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to an anti-cancer medicine. Polivy is used to treat ...

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line ...

Polivy (polatuzumab vedotin-piiq) is a prescription biologic drug that treats certain types of B-cell lymphoma. Polivy can cause side effects that range from mild to serious. Examples include ...

Margot Polivy, a dauntless lawyer who played a key role in the enactment and enforcement of Title IX, the landmark federal legislation of the 1970s that vastly expanded opportunities for women in ...